GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TIL
Instil Bio is a biotech company developing cell therapies for cancer treatment. Its stock price is a venture bet on the success of its complex scientific platform. The chart reflects high volatility, dependence on lab news, and the need for funding.
Share prices of companies in the market segment - Oncology cell gene therapy
Instil Bio, Inc. is a biotechnology company developing tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors. We classify this technology as "Cell-Gene Therapy for Cancer," one of the most advanced areas in oncology. The graph below illustrates the dynamics of this complex and promising sector.
Broad Market Index - GURU.Markets
Instil Bio is a biotech company developing tumor-infiltrating lymphocyte (TIL)-based cell therapy for the treatment of solid tumors. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
TIL - Daily change in the company's share price TIL
The volatility of Instil Bio, an oncology company, is measured by change_co. It reflects its sensitivity to news about the clinical trials of its cell therapy. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Instil Bio, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with TIL's performance, which depends on the results of its cell therapy clinical trials, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Instil Bio is a biotech company developing cell therapy for solid tumors. Its shares, like many in the sector, are extremely volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TIL
Instil Bio, Inc.'s year-over-year performance tells the story of developing tumor-infiltrating lymphocyte (TIL)-based cell therapy. Its 12-month market cap reflects its struggles with production and clinical challenges. Its valuation reflects investors' faith in the company's ability to overcome these obstacles and bring this promising cancer treatment to market.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Instil Bio, Inc. is a biotech company developing cancer immunotherapy using tumor-infiltrating lymphocytes (TILs). Its stock price is entirely dependent on clinical trial results and regulatory decisions. This reflects the enormous potential of its unique technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Instil Bio is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TIL
Instil Bio develops cell therapy for cancer. Its monthly price fluctuations reflect the complex and expensive scientific process. News about clinical trial successes and manufacturing advances are key events that can trigger sharp price movements.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
This chart reflects the dynamics of the biotech sector, particularly in cell therapy. For Instil, a clinical-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in cancer treatment are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Instil Bio is a biotech company developing cell therapy based on tumor-infiltrating lymphocytes (TILs) for the treatment of cancer. This is a cutting-edge but high-risk field. The overall market chart provides only background information, while Instil Bio's performance is driven by development news, which is typical for the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TIL
Shares of Instil Bio, a cancer cell therapy company, reflect the complexity and potential of this cutting-edge field every week. The price movement is a direct response to the results of clinical trials of their personalized treatments, where the stakes are extremely high.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Instil Bio develops cell therapy for cancer, one of the most advanced and risky areas of biotech. The chart below is your guide: are the company's weekly stock surges and declines related to its own clinical data, or do they reflect the general hopes and disappointments of investors in the gene therapy field?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Instil Bio is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Instil Bio exist in its own world of clinical trials, or are the overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
TIL - Market capitalization of the company TIL
Instil Bio's market capitalization tells a dramatic story of high hopes for cell therapy for solid tumors. Its sharp decline reflects disappointing clinical trial results and subsequent restructuring. The dynamics are a clear example of high risks and biotech developments.
TIL - Share of the company's market capitalization TIL within the market segment - Oncology cell gene therapy
Instil Bio is a biotech company focused on developing cell-based therapies (TILs) for the treatment of solid tumors. Its market capitalization reflects both the significant potential of this personalized approach and the high risks of clinical development. The chart shows how the market views its chances in this cutting-edge field of oncology.
Market capitalization of the market segment - Oncology cell gene therapy
Instil Bio is a company developing cell therapies for cancer treatment. The chart below shows the overall market capitalization of this cutting-edge sector. Its volatility reflects both the enormous hopes for a breakthrough in cancer treatment and the high risks associated with clinical trials of such complex technologies.
Market capitalization of all companies included in a broad market index - GURU.Markets
Instil Bio is a company working in the cutting-edge field of cancer cell therapy. Its market cap reflects a bet that patients' own immune cells, modified in the lab, can become a powerful weapon against tumors. Its volatility on the overall chart reflects the hopes and setbacks at the cutting edge of science.
Book value capitalization of the company, segment and market as a whole
TIL - Book value capitalization of the company TIL
Instil Bio's book value is the capital invested in the development and clinical trials of personalized cell therapy for cancer treatment. This is a tangible, science-intensive foundation for one of the most advanced areas of oncology. How has this capital-intensive asset evolved? The chart below tells its complex story.
TIL - Share of the company's book capitalization TIL within the market segment - Oncology cell gene therapy
Instil Bio develops cell therapies for cancer treatment, which requires sterile manufacturing facilities to handle patient cells. The chart shows the share of these unique and expensive tangible assets, reflecting the physical foundation of its personalized medicine.
Market segment balance sheet capitalization - Oncology cell gene therapy
Cancer cell therapy, like Instil Bio's, is at the cutting edge of science. At the research stage, the company doesn't require huge factories. A graph of its book value shows how modest its physical assets are, while its intellectual property can be worth billions.
Book value of all companies included in the broad market index - GURU.Markets
Instil Bio is a factory producing "living drugs" for cancer. The company's book value is derived from its advanced cell therapy production facilities, laboratories, and cryogenic storage facilities. The chart shows the physical scale of the infrastructure required to create personalized cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TIL
Instil Bio owns cell therapy plants. But its market price is a barometer of faith in its scientific approach. The chart shows how expectations for clinical trials can create a huge premium on its stock, which, however, can quickly evaporate in the event of failure. This is a pure bet on science.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Instil Bio is a biotech company focused on cell therapy for cancer treatment. Its value lies in its scientific platform and potential to save lives. This chart demonstrates the market's enormous expectations for its innovative treatments, compared to its modest balance sheet assets.
Market to book capitalization ratio for the market as a whole
Instil Bio is a pioneer in cell therapy, using a patient's own tumor-infiltrating lymphocytes (TILs) to fight cancer. The company's value lies in its sophisticated scientific and manufacturing platform. This chart reflects the overall valuation, but how is the market trying to assess the potential of personalized medicine in oncology?
Debts of the company, segment and market as a whole
TIL - Company debts TIL
Instil Bio operates in cell therapy, one of the most capital-intensive areas of biotechnology. This chart clearly demonstrates the enormous resources required to fund research and build specialized manufacturing facilities capable of creating personalized cancer treatments.
Market segment debts - Oncology cell gene therapy
Instil Bio develops tumor-infiltrating lymphocyte (TIL)-based cell therapies for cancer treatment. This is one of the most advanced and expensive areas of research in oncology. This chart illustrates how the company is raising the massive capital needed to fund its complex clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TIL
Instil Bio specializes in cancer cell therapy, one of the most capital-intensive areas of biotech. This chart reflects how aggressively the company leverages its cutting-edge research and clinical programs. It's a bet on a scientific breakthrough, where leverage can mean the difference between triumph and ruin.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Instil Bio is a biotech company focused on cell therapy for cancer treatment. This chart reflects financial leverage in the cutting-edge and capital-intensive oncology sector. It allows one to assess how the industry as a whole finances its expensive research and how Instil Bio's capital management strategy compares to this trend.
Debt to book value of all companies in the market
Instil Bio is a biotech company developing cell therapy for cancer. This is a cutting-edge but extremely expensive field, where financing is through equity sales rather than debt. This chart, which reflects debt trends across the economy, highlights the contrast between capital-intensive industries and knowledge-intensive companies whose primary asset is intellectual property.
P/E of the company, segment and market as a whole
P/E - TIL
For Instil Bio, a cancer cell therapy company, this chart represents investor expectations. Its value reflects not current profits, but rather belief in the potential of its approach using tumor-infiltrating lymphocytes (TILs). It's a high-risk assessment of a future breakthrough in personalized oncology.
P/E of the market segment - Oncology cell gene therapy
The cancer cell therapy being developed by Instil Bio is personalized medicine. This chart shows the average rating for biopharmaceutical companies. It helps us understand that Instil Bio, with its technology using a patient's own tumor lymphocytes, is being evaluated based on the potential of this complex but promising approach.
P/E of the market as a whole
Instil Bio, Inc. works in the field of cell therapy, developing cancer treatments using a patient's own immune cells (tumor-infiltrating lymphocytes). This is the personalized medicine of the future. This biotech sentiment chart helps understand how the market views this complex but potentially revolutionary technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TIL
Instil Bio is a biotech company focused on cell therapy for solid tumors. This chart illustrates investor expectations, which are entirely dependent on progress in clinical trials. The dynamics reflect the market's assessment of the scientific potential of its approach and the likelihood of future commercial success.
%20P%2FE%20TIL&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TIL&v=1772537982857 "Chart of the company's future (projected) P/E TIL")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Instil Bio specializes in developing tumor-infiltrating lymphocyte (TIL)-based cell therapies for cancer treatment. This chart shows profitability expectations in the cell therapy sector. It provides insight into the market's appreciation for the prospects of this complex, yet potentially breakthrough, technology in the fight against solid tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772537982926 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Instil Bio is a clinical-stage biotech company specializing in the development of tumor-infiltrating lymphocyte (TIL)-based cell therapies for cancer treatment. This chart reflects the overall sentiment in the healthcare sector. For a company working on personalized treatments, it shows how much investors believe in the future of cell technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772537982950 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TIL
Instil Bio is at the forefront of cancer cell therapy, developing treatments using tumor-infiltrating lymphocytes (TILs). The financial results shown here represent net investments in research and clinical trials. This chart shows the cost of developing next-generation personalized cancer therapies.
Profit of companies in the market segment - Oncology cell gene therapy
Instil Bio specializes in developing tumor-infiltrating lymphocyte (TIL)-based cell therapy for the treatment of solid tumors. This personalized approach utilizes the patient's own immune cells. This graph reflects the high potential and complexity of the cell therapy sector, where Instil Bio's success could mean a breakthrough in cancer treatment.
Overall market profit
Instil Bio is a biotech company developing cell therapies for cancer. Its success depends on long-term, risk-taking investments in research and development, not on current economic conditions. However, as this chart shows, it is precisely during periods of rising corporate profits that the market has the available capital and risk appetite to fund such breakthrough projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TIL
Instil Bio is a biotech company specializing in the development of cell therapies (TILs) for the treatment of solid tumors. The profit (or, currently, loss) forecast on this chart represents analysts' assessment of the likelihood of success for its clinical programs. The trajectory reflects high research costs and the enormous potential revenue if the therapy is approved.
%20profit%20of%20the%20company%20TIL&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TIL&v=1772537983115 "Graph of future (projected) profit of the company TIL")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Instil Bio is at the forefront of oncology, developing tumor-infiltrating lymphocyte (TIL)-based cell therapies for the treatment of solid tumors. This chart shows the profitability forecast for the entire cell and gene therapy sector, providing insight into how investors and analysts view the commercial prospects of this complex yet promising field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772537983142 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Instil Bio works in the field of cancer cell therapy, which requires significant investment in research and production. The overall investment climate, which this graph indirectly reflects, is critical for such companies. Positive economic expectations facilitate raising funds for long-term, capital-intensive research and development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772537983144 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TIL
Instil Bio is a biotech company developing cell therapy for solid tumors. This chart shows a speculative estimate of its potential future revenue. Investors are investing in the hope that its complex but promising technology will lead to a breakthrough in cancer treatment.
P/S market segment - Oncology cell gene therapy
Instil Bio is a biotech company working in the cutting-edge field of cancer cell therapy. It develops treatments using a patient's own immune cells (tumor-infiltrating lymphocytes) to combat solid tumors. This chart reflects investor expectations in the sector, showing how the market views the potential of this complex yet promising technology.
P/S of the market as a whole
Instil Bio is a biotech company specializing in the development of cell-based therapies (TILs) for the treatment of solid tumors. This is one of the most advanced and complex approaches in oncology. This chart helps investors understand the market's willingness to fund breakthrough, yet capital-intensive, research in the hopes of future commercial success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TIL
Instil Bio is a biotech company working in cell therapy for cancer treatment. This chart shows the company's valuation relative to its future, currently hypothetical, sales. It measures investor expectations that its innovative technology for treating solid tumors will prove effective and reach the market.
%20P%2FS%20TIL&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TIL&v=1772537983308 "The graph of the company's future (projected) P/S TIL")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Instil Bio specializes in developing tumor-infiltrating lymphocyte (TIL)-based cell therapies for the treatment of solid tumors. This is a cutting-edge and complex approach in oncology. This chart reflects investor expectations for the company's potential breakthrough and future revenue compared to other cell and gene therapy companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772537983343 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Instil Bio works in the field of cancer cell therapy. The company's future depends entirely on the success of its clinical programs and regulatory approvals. This graph of overall expectations for TIL is merely a backdrop. The company's value is determined by scientific breakthroughs and investor confidence in its technological platform, not by the overall economic situation or market revenue growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772537983390 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TIL
This chart depicts the financial model of a biotech company focused on cell therapy. For Instil Bio, which develops cancer treatments using tumor-infiltrating lymphocytes (TILs), it shows the funds raised from funding and partnerships to conduct expensive clinical trials.
Sales of companies in the market segment - Oncology cell gene therapy
Instil Bio specializes in cell therapy for solid tumors using tumor-infiltrating lymphocytes (TILs). This cutting-edge approach has the potential to transform oncology. This graph illustrates the sector's growth, and the commercialization of Instil Bio's therapy could be a key driver, ushering in a new era of cancer treatment.
Overall market sales
Instil Bio is a biotechnology company specializing in cancer cell therapy using tumor-infiltrating lymphocytes (TILs). Its developments are at the forefront of personalized oncology. The company's success depends on scientific breakthroughs and reflects the growth of the high-tech medical sector, which is shaping the economy of the future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TIL
Instil Bio is a biotechnology company working in the cutting-edge field of cell therapy for solid tumors using tumor-infiltrating lymphocytes (TILs). Future sales projections depend solely on the success of its complex clinical trials. This graph reflects the high risks and potentially enormous rewards of this innovative field.
%20sales%20of%20the%20company%20TIL&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TIL&v=1772537983627 "Schedule of future (projected) sales of the company TIL")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Instil Bio is a biotech company specializing in cell therapy for cancer treatment. The oncology sector outlook, particularly in the gene and cell therapy segment, reflects expectations for this revolutionary field. The chart illustrates the significant market potential for personalized cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772537983712 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Instil Bio is a biotech company developing cell therapies for cancer treatment. Its value is determined by the potential of its scientific developments, not economic cycles. The overall economic situation, reflected in this chart, is important for the availability of funding for the capital-intensive clinical trials required to bring a product to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772537983960 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TIL
Instil Bio is a biotech company specializing in developing cell therapies for the treatment of solid tumors. Its financial activities are entirely focused on expensive clinical trials. This chart shows its capital burn rate—a key metric for companies seeking to create breakthroughs in oncology.
Market segment marginality - Oncology cell gene therapy
Instil Bio is a biotechnology company working in the cutting-edge field of cell therapy for cancer treatment. For such companies, profitability is a long-term goal, dependent on the success of clinical trials. This metric reflects its operational structure and the intensity of its investment in research compared to other cell gene therapy developers.
Market marginality as a whole
Instil Bio, Inc. is a biotechnology company working in cell therapy for cancer treatment. This chart shows overall profitability. In contrast, Instil Bio demonstrates the enormous costs associated with developing personalized drugs. Its financial performance reflects an investment in science in the hopes of future profitability from breakthrough therapies.
Employees in the company, segment and market as a whole
Number of employees in the company TIL
Instil Bio specializes in developing cell therapies (TILs) for the treatment of solid tumors. Its team is primarily comprised of scientists and complex manufacturing specialists. The dynamics in this chart reflect investments in clinical development and the creation of manufacturing capacity, a critical and capital-intensive process in this field.
Share of the company's employees TIL within the market segment - Oncology cell gene therapy
Instil Bio is a pioneer in cancer cell therapy using tumor-infiltrating lymphocytes (TILs). This chart highlights its concentration of unique talent. It reflects the significant proportion of leading scientists, immunologists, and cell manufacturing specialists in this cutting-edge and complex oncology field that Instil Bio brings together.
Number of employees in the market segment - Oncology cell gene therapy
Instil Bio is a biotechnology company specializing in cancer cell therapy. This graph demonstrates the complexity and research-intensive nature of personalized oncology. The growing number of highly qualified specialists reflects the development of one of the most promising, yet also most challenging, areas in modern medicine.
Number of employees in the market as a whole
Instil Bio is a biotechnology company specializing in cancer cell therapy. This sector is one of the most research-intensive. The presented employment chart reveals little about the state of affairs at Instil Bio, where hiring top scientists and clinicians depends on research progress and investment, not macroeconomic indicators.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TIL (TIL)
Instil Bio works in cancer cell therapy using tumor-infiltrating lymphocytes (TILs). This is a highly complex, personalized manufacturing process. This chart shows how the market values companies at the forefront of medicine. The high market capitalization per employee reflects not only scientific potential but also the value of a unique and complex manufacturing platform.
%20of%20the%20company%20TIL%20(TIL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TIL-TIL&v=1772537984445 "Chart of market capitalization per employee (in thousands of dollars) of the company TIL (TIL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Instil Bio specializes in cancer cell therapy, a cutting-edge and complex technology. Success depends on a small team of highly qualified scientists. This figure demonstrates the enormous value the market places on each of the company's specialists, anticipating a breakthrough in cancer treatment, which distinguishes the company from traditional pharmaceutical companies.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772537984499 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Instil Bio specializes in developing cell therapies (TILs) for the treatment of solid tumors. This is a personalized and sophisticated approach to cancer treatment. This chart reflects the high market valuation per employee typical of biotech companies at the forefront of science, where intellectual capital and technology potential determine the entire value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772537984572 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TIL (TIL)
Instil Bio is a biotech company working in the field of cell therapy (TIL) for cancer treatment. This is one of the most complex and personalized areas of medicine, requiring R&D and sophisticated manufacturing. This figure is likely deeply negative, reflecting the enormous cost of research and development per highly qualified scientist.
%20Chart%20TIL%20(TIL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TIL-TIL&v=1772537984654 "Company Profit Per Employee (in thousands of dollars) Chart TIL (TIL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Instil Bio specializes in cancer cell therapy, a cutting-edge but extremely expensive field to research. The chart below sets a profitability benchmark, which for R&D-stage companies like TIL is often negative. Their goal isn't current efficacy, but a future breakthrough that will allow a single approved drug to significantly exceed industry profit margins.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772537984715 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Instil Bio specializes in cancer cell therapy, one of the most research-intensive and expensive areas of medicine. During the development and clinical trials stages, the company incurs enormous R&D expenditures. This chart shows the scale of this investment in people and reflects the phase the company is in: either burning cash for a future revolution or already beginning commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772537984849 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TIL (TIL)
Instil Bio works in the field of cancer cell therapy, which requires significant investment in research. This chart shows that the company is in the development stage. It demonstrates the potential: if its therapeutic approaches are successful, revenue per specialist could be extremely high, reflecting the value of cutting-edge scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TIL-TIL&v=1772537984855 "Sales chart per company employee TIL (TIL)")
Sales per employee in the market segment - Oncology cell gene therapy
Instil Bio is a biotech company focused on developing cell therapies (TILs) for the treatment of solid tumors. This is cutting-edge, yet capital-intensive, science. This metric is likely low at the R&D stage, but it reflects how effectively their team of scientists and technicians generates revenue (e.g., from partnerships) per employee.
Sales per employee for the market as a whole
Instil Bio is a biotech company working in the field of cell-based cancer therapy (TIL), one of the most advanced and complex areas in medicine. This chart shows revenue per employee. For a clinical-stage company with no commercial product, this figure is expectedly close to zero. The entire staff is focused on science and clinical trials, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company TIL (TIL)
Instil Bio works in the field of cell therapy (TIL) for cancer treatment. This is one of the most advanced, yet complex, areas in oncology. This chart shows bearish sentiment. Bears may bet that the manufacturing process will prove too complex and expensive, or that clinical trials will not confirm the therapy's effectiveness, leading to a devaluation of the entire platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TIL-TIL&v=1772537985013 "Short Shares Chart for the Company TIL (TIL)")
Shares shorted by market segment - Oncology cell gene therapy
Instil Bio specializes in cell therapy (TIL) for the treatment of solid tumors. This is a cutting-edge but highly complex segment of biotech. This chart shows overall short positions in the cell therapy sector. High values reflect investor doubts about the technology across the industry, anticipating production issues or the effectiveness of such complex treatments.
Shares shorted by the overall market
Instil Bio (TIL) is a clinical-stage biotech company working in cell therapy. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they require constant refinancing for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TIL (TIL)
Instil Bio is a clinical-stage biotech company focused on cell therapy. The stock is extremely volatile. This chart can surge above 70 on positive R&D news. Oversold territory (<30) is often associated with setbacks, delays, production issues, or a general downturn in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TIL-TIL&v=1772537985122 "RSI 14 indicator chart for the company's stock TIL (TIL)")
RSI 14 Market Segment - Oncology cell gene therapy
Instil Bio (TIL) is "CAR-T" 2.0. They "grow" the patient's own T-cells (TILs) (from the tumor) to attack cancer. RSI_14_Seg for "Oncology cell gene therapy" (biotech) shows the overall sentiment. It helps us understand: is TIL's volatility just their "TIL platform" or is the entire sector "overheated"?
RSI 14 for the overall market
Instil Bio (TIL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TIL (TIL)
Instil Bio (TIL) is a biotech company specializing in cell therapy (TIL) for the treatment of solid tumors. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this technology and the risks associated with its clinical development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TIL-TIL&v=1772537985289 "A chart showing analyst consensus forecasts for the expected stock price. TIL (TIL)")
The difference between the consensus estimate and the actual stock price TIL (TIL)
Instil Bio is a biotech company focused on developing TIL (tumor-derived T cell) therapy for cancer treatment. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their view on the value of the company's assets and technologies after the R&D restructuring.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TIL-TIL&v=1772537985427 "A chart showing the difference between the consensus forecast and the actual stock price. TIL (TIL)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Instil Bio is a biotech company developing cell therapies (TILs) for the treatment of solid tumors. This chart shows analysts' overall expectations for the cell and gene therapy sector. It reflects their confidence in the effectiveness of this technology and the company's ability to commercialize it.
Analysts' consensus forecast for the overall market share price
Instil Bio is a biotech company working at the cutting edge of cell therapy. They use TILs (tumor-infiltrating lymphocytes) to fight cancer. This chart shows overall market sentiment. For Instil, a "science" startup, how risk appetite (sentiment) influences funding for their expensive R&D platform is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TIL
Instil Bio is a biotech company working in one of the most challenging areas of cell therapy—TILs (tumor-infiltrating lymphocytes). Their approach involves harvesting a patient's own immune cells from their tumor, expanding them, and infusing them back into the body. This graph is a clear indicator of their faith in R&D, reflecting their ability to overcome enormous manufacturing and clinical challenges.
AKIMA Market Segment Index - Oncology cell gene therapy
Instil Bio is a biotech company specializing in cell therapy (TIL) for the treatment of solid tumors. TIL technology utilizes a patient's own immune cells. This chart shows the average index for the cell therapy sector. It helps investors assess how Instil Bio's scientific approach compares to the industry average.
The AKIM Index for the overall market
Instil Bio is a biotech company that has pivoted from TIL cell therapy to developing bispecific antibodies in China. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, as it undergoes a strategic pivot, compares to overall economic trends.
